Multidisciplinary

No drama: Self-injury may be sign of internal, external conflicts

Stephen Padilla, 17 minutes ago

The belief that individuals who commit nonsuicidal self-injury (NSSI) are doing it only to seek attention only perpetuates the stigma and prevents these people from seeking appropriate treatment and psychological care, according to a Singapore study.

ESRD, hyperparathyroidism tied to penile calciphylaxis

an hour ago

A recent study that defined the disease course of penile calciphylaxis has reported high mortality among patients with such condition and suggests imaging to aid in its diagnosis. End-stage renal disease, hyperparathyroidism, and normal body mass index are significantly associated with this rare disorder.

AZD7442 cocktail protects against symptomatic COVID-19 illness

Elaine Soliven, 12 hours ago

Intramuscular administration of single-dose AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab and cilgavimab), significantly reduced the risk of developing symptomatic COVID-19 in adults, according to the PROVENT* study presented at IDWeek 2021.

Roflumilast cream eases itch burden, severity in chronic plaque psoriasis

Roshini Claire Anthony, 18 hours ago

In patients with chronic plaque psoriasis, once-daily treatment with roflumilast improved severity and burden of itch compared with vehicle cream, according to results of the phase III DERMIS-1 and DERMIS-2 trials presented at EADV 2021.

Surgical repair of POH ups QoL, confers low complication risk

18 hours ago

Acute surgical repair of large para-oesophageal hernias (POH) can be safely performed, yielding low morbidity and mortality rates, and leads to improved quality of life (QoL) among patients, a recent study has found.

A new paradigm for T2DM care in the era of SGLT-2i

01 Oct 2021

During the recent EMPIRE SUMMIT, Professor Dr Chee Kok Han discussed the importance of an early, patient-centred,multi factorial approach in managing type 2 diabetes mellitus(T2DM). Specifically, Professor Chee highlighted the role ofempagliflozin (Jardiance®, Boehringer Ingelheim) in conferring cardiorenal protection to patients with T2DM.

Early-initiation-of-Enstilar--in-managing-plaque-psoriasis-provides-better-patient-outcomes

01 Oct 2021

Psoriasis is characterised by well-circumscribed, erythematous, scaly plaques and can be categorised as eitherlocalised or generalised, depending on the severity of the disease and its impact on patients’ quality of life. The mainstay of treatment for localised disease includes topical therapy with corticosteroids, calcipotriene and coal tar products, while generalised psoriasis may require more advanced forms of treatment like phototherapy and systemic therapy. In this case study, Dr Preamala Gunabalasingam shares her clinical experience treating.2plaque psoriasis with a combined formulation of betamethasone dipropionate and calcipotriol monohydrate in a single spray foam (Enstilar® Foam, LEO Pharma).

Optimising glycaemic control with FreeStyle Libre™ for better patient management

15 Sep 2021

The FreeStyle Libre™ flash glucose monitoring system includes a sensor which automatically measures and continuously stores up to 8 hours of glucose readings, allowing patients to monitor their glucose levels without the need for painful finger pricks. Physicians play an important role in reviewing and analysing glucose data that is available through LibreView to support patient management.

AZD7442 cocktail protects against symptomatic COVID-19 illness

Elaine Soliven, 20 Oct 2021

Roflumilast cream eases itch burden, severity in chronic plaque psoriasis

Roshini Claire Anthony, 19 Oct 2021

Abrocitinib trumps dupilumab for itch relief in eczema

Pearl Toh, 16 Oct 2021

The oral selective JAK*1 inhibitor abrocitinib is superior to dupilumab for relieving itch and achieving skin clearance in people with moderate-to-severe atopic dermatitis (AD), according to results from a head-to-head comparison in the JADE DARE trial presented at EADV 2021.

Baricitinib: A potential treatment for alopecia areata?

Roshini Claire Anthony, 14 Oct 2021

Baricitinib, an oral, selective Janus kinase (JAK)1/JAK2 inhibitor, may help improve hair growth in patients with severe alopecia areata, according to results from the phase III BRAVE-AA1 and BRAVE-AA2 trials.